Combined modality treatment for locally advanced gastric cancer. 2003

Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
Radiation Oncology Department, Centro di Riferimento Oncologico (CRO), Istituto Nazionale Tumori, Via Pedemontana Occidentale 12, 33081 Aviano, PN, Italy. adepaoli@cro.it

The positive results recently reported by the Intergroup 0116 Study with adjuvant chemoradiation have stimulated an increasing interest in the combined modality treatment of gastric cancer. The significant improvement in disease-free and overall survival reported in this study was related mainly to an improvement in local control rather than to a decrease in the incidence of metastatic disease. Therefore, new and potentially more effective chemotherapy regimens could be considered and the feasibility of their integration with radiation therapy needs to be explored to further improve the treatment in gastric cancer. Our experience with combined radiation therapy and 5-FU-with or without 5-FU based chemotherapy--in unresectable and in partially or radically resected gastric cancer is retrospectively reviewed. In addition, an initial prospective evaluation of the feasibility and toxicity of radiation and 5-FU following adjuvant chemotherapy with modern platinum containing regimens is reported. Our data and the current available experiences with investigational approaches in gastric cancer involving preoperative chemotherapy and intraoperative radiotherapy will be considered in exploring a new combined modality treatment program.

UI MeSH Term Description Entries
D007432 Intraoperative Period The period during a surgical operation. Intraoperative Periods,Period, Intraoperative,Periods, Intraoperative
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 2003, Acta chirurgica Belgica,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 1998, Tumori,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 1996, Cancer investigation,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
May 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 1992, International journal of radiation oncology, biology, physics,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
August 2012, The British journal of surgery,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
March 1985, Seminars in oncology,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 2004, Klinichna khirurhiia,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
January 2003, Diseases of the colon and rectum,
Antonino De Paoli, and Angela Buonadonna, and Giovanni Boz, and Davide Lombardi, and Roberto Innocente, and Salvatore Tumolo, and Giancarlo Tosolini, and Carlo Rossi, and Mauro G Trovò, and Sergio Frustaci
March 1994, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!